Tue, Jul 14 · 8:30

The inaugural Biomarkers for Alzheimer’s Disease Summit is the industry’s only forum dedicated to solving the challenges of developing clinically validated biomarkers for the earlier detection and diagnosis of Alzheimer’s Disease, that are predictive of outcome measures and accurately reflect a therapeutic effect on target engagement.

[N.b. COVID-19 risk-free registration policy applies**]

With an emphasis on looking beyond amyloid and tau and diversifying the biomarker landscape, this meeting delves into blood-based biomarkers, neuroinflammatory markers, NFL, microglial activation, exosomes and CSF synaptic biomarkers. Through open reflections and sharing competitive knowledge, this meeting will enable drug developers to scale the hurdles preventing the identification and validation of biomarkers to accelerate the development of disease modifying therapeutics for Alzheimer’s.

Join drug developers and academics at the Biomarkers for Alzheimer’s Disease Summit. This is your opportunity to discuss in-depth the cutting-edge advances in biomarker science, convey lessons learned and network to build long lasting partnerships.

**In light of the current COVID-19 situation, a risk-free booking policy applies so that you can register with peace of mind if the meeting cannot run due to COVID-19. Check out the website for full details.

Brochure https://go.evvnt.com/643552-3?pid=5731

Conference Only - Industry Pricing - Register by May 15: USD 2499.0,
Conference Only - Academic Pricing - Register by May 15: USD 2099.0,
Conference Only - Industry Pricing - Register by June 12: USD 2699.0,
Conference Only - Academic Pricing - Register by Jue 12: USD 2299.0

Speakers: Felix Yeh, Head of Biomarkers, Alector, Kirk Brown, Director, CNS Early Development, Alnylam Pharmaceuticals, Martin Tolar, CEO, Founder, Alzheon, Philip Ashton-Rickardt, Senior Vice President, Immunology, AZTherapies, Christopher Whelan, Senior Scientist, Biogen, Danielle Graham, Senior Director, Discovery and Clinical Biomarkers, Biogen, Lindsay Burns, SVP of Neuroscience, Cassava Sciences, Inc, Richard Wyse, Global Director of Research and Development, Cure Parkinson’s Trust UK, Christopher Winrow, Senior Director, Clinical Development - Neuroscience Program Lead, Cyclerion, Yaming Wang, Neuroinflammation Lead, Neurodegeneration Research, Eli Lilly, Christopher (CJ) Barnum, Director of Neuroscience, INmune Bio, Dimitrios Kapogiannis, Clinical Investigator, Laboratory of Clinical Investigation, National Institute on Aging, NIH , Adjunct Associate Professor, Dept. of Neurology, National Institute of Health, Scott Shandler, Founder and CEO, Longevity Biotech, Johan Luthman, Executive Vice President, Research and Development, Lundbeck, Steven Arnold, Professor of Neurology, Harvard Medical School, Translational Neurology Head, MGH Interdisciplinary Brain Center, Rhoda Au, Professor of Anatomy, Neurobiology, Framingham Heart Study, Boston University Schools of Medicine, Daniel Alkon, President, Neurotrope Bioscience, Pablo Sardi, Head, Lysosomal Storage and Metabolic Diseases, Sanofi, Jonathan Levenson, Vice President of Translational Biology, Tiaki Therapeutics, David Mengel, Department of Neurodegenerative Diseases, University of Tübingen and Hertie- Institute for Clinical Brain Research, Mark Frasier, Senior Vice President Research Programs, Michael J Fox Foundation